We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Xi'an Tianlong Science & Technology Co., Ltd

Tianlong is an innovative, high-technology company that provides professional PCR detection devices, reagent kits and... read more Featured Products: More products

Download Mobile App

TianLong HPV Nucleic Acid Detection Kit Could Enable Early Detection of Cervical Cancer

By LabMedica International staff writers
Posted on 02 Feb 2024
Print article
Image: Tianlong’s HPV detection kit covers 18 high-risk HPV types (Photo courtesy of TianLong)
Image: Tianlong’s HPV detection kit covers 18 high-risk HPV types (Photo courtesy of TianLong)

Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union. Each year, there are around 33 000 cases of cervical cancer in the EU, and 15,000 deaths. The primary cause of cervical cancer is a persistent infection of the genital tract by some specific types of human papillomavirus (HPV). HPV is present in most cases of cervical lesions, which can further develop into cancer.

Vaccination rates and the incidence of cervical adenocarcinoma are both on the rise, making HPV genotype testing an important tool to help stratify risk and guide patient management. High-risk HPV genotypes 16, 18 account for 70% of cervical cancer worldwide. Tianlong’s Human Papillomavirus (HPV) Nucleic Acid Detection Kit is a qualitative in vitro test for detection of 18 high-risk HPV types (HPV 16,18,26,31,33,35,39,45,51,52,53,56,58,59,66,68,73 and 82), which can specifically identify types of HPV 16 and HPV 18 while concurrently detecting the rest of other high-risk types.


  • High Precision:
  • The coefficient of variation of the Ct values (CV%) is less than 5%
  • More accurate:
  • Collocating with Tianlong extraction reagent makes your experiment results more accurate
  • Internal Control:
  • The use of internal control system in the kit can effectively prevent false negative results
  • User-friendly:
  • Applicable in instruments with FAM, HEX/VIC,CY5 and TEXAS RED/ROX channels
  • Concurrently detects remaining 16 HPV genotypes:
  • 26,31,33,35,39,45,51,52,53,56,58,59,66,68,73,82 Positive or Negative Pooled Result

About TianLong

TianLong Science and Technology Co., Ltd.(Shaanxi, China) is a Chinese manufacturer dedicated to molecular diagnosis instruments and kits for over 26 years, with IS013485, CE certificated, providing integrated PCR lab solutions and OEM service.

For more information or inquiries, please contact Tianlong team directly.  


Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The blood test uses AI to predict Parkinson’s seven years before onset of symptoms (Photo courtesy of Kateryna Kon/Shutterstock)

AI-Powered Blood Test Predicts Parkinson's Seven Years before Symptoms Appear

Parkinson’s disease is currently the fastest-growing neurodegenerative disorder worldwide, affecting nearly 10 million people globally. It is a progressive disease caused by the deterioration and death... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.